Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Summary Background In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy, in which we...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2017-08, Vol.16 (8), p.591-600
Hauptverfasser:	Chan, Dennis, PhD, Binks, Sophie, MRCP, Nicholas, Jennifer M, PhD, Frost, Chris, Prof, Cardoso, M Jorge, PhD, Ourselin, Sebastien, Prof, Wilkie, David, MA, Nicholas, Richard, PhD, Chataway, Jeremy, Dr
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Atrophy Clinical trials Cognition & reasoning Cognitive ability Cognitive Dysfunction - drug therapy Cognitive Dysfunction - etiology Double-Blind Method Executive Function - drug effects Executive Function - physiology Fab Female Frontal lobe Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Information processing Intelligence Male Memory Memory Disorders - drug therapy Memory Disorders - etiology Mental depression Middle Aged Motivation Multiple sclerosis Multiple Sclerosis, Chronic Progressive - complications Multiple Sclerosis, Chronic Progressive - drug therapy Nervous system Neurology NMR Nuclear magnetic resonance Outcome Assessment (Health Care) Patients Pattern recognition Quality of Life Rehabilitation Simvastatin Simvastatin - administration & dosage Simvastatin - pharmacology Visual perception
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!